(Reuters) - Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals ...

The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...

Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than Alexion Pharmaceuticals Inc's Soliris, in a ...

More than a year after Apellis Pharmaceuticals proved its C3 inhibitor pegcetacoplan could go head-to-head with industry heavyweight Soliris in patients with the rare blood disorder paroxysmal ...

(RTTNews) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major ...

An interchangeable product can be expected to produce the same clinical result as the reference product in any given patient. The Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb ...

While Alexion has four revenue-generating products, 70% of the company's sales have come from one drug, Soliris. This treatment, which is provided once every two weeks via intravenous injection, ...